| Name | Doxylamine succinate |
| Description | Doxylamine Succinate is a pyridine derivate histamine H1 antagonist with pronounced sedative properties. Doxylamine succinate (Decapryn) competitively blocks the histamine H1 receptor and limits the typical allergic and anaphylactic responses, including bronchoconstriction, vasodilation, increased capillary permeability, and spasmodic contraction of the gastrointestinal smooth muscle, caused by actions of histamine on bronchial and gastrointestinal smooth muscles, and on capillaries. This drug also prevents histamine-induced pain and itching of the skin and mucous membranes. |
| In vitro | In B6C3F1 mice, the impact of Doxylamine on microsomal enzyme activity and serum thyroid hormone levels was investigated by administering Doxylamine succinate for 7 or 15 days with dietary incorporation at levels of 0, 40, 375, 750, or 1500 ppm, corresponding to the free base form of Doxylamine. Findings reveal that Doxylamine acts as an inducer of hepatic microsomal cytochrome P450 enzymes, consistent with the hypothesis that Doxylamine increases liver enzyme activities involved in T4 metabolism in B6C3F1 mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 100 mg/mL (257.43 mM)
H2O : 100 mg/mL (257.43 mM)
|
| Keywords | B6C3F1 mice | Low toxicity | Liver | inhibit | Subcutaneous infiltration | Doxylamine Succinate | Doxylamine succinate | Inhibitor | Histamine Receptor | Local analgesic | Doxylamine |
| Inhibitors Related | Meclizine dihydrochloride | Lidocaine | Famotidine | Alginic acid |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
